Literature DB >> 25248339

Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.

Naoki Izawa1, Yusuke Onozawa, Tomomi Hikosaka, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Nozomu Machida, Yutaka Haraguchi, Hirofumi Ogawa, Tetsuo Nishimura, Masahiro Nakagawa, Tomohito Fuke, Yoshiyuki Iida, Tomoyuki Kamijo, Tetsuro Onitsuka, Narikazu Boku, Hirofumi Yasui, Tomoya Yokota.   

Abstract

BACKGROUND: We evaluated the efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC) with a high risk of distant metastases compared with CRT alone.
METHODS: We retrospectively analyzed 29 HNSCC patients with clinical nodal stage N2c, N3, or N2b disease and supraclavicular lymph node metastases receiving CRT alone (CRT group; n = 16) or TPF induction chemotherapy followed by CRT (TPF group; n = 13) between April 2008 and May 2012.
RESULTS: The median follow-up periods were 14.5 (range 5.0-65.0) and 25.0 (range 14.0-32.0) months for CRT and TPF groups, respectively. A greater proportion of patient characteristics in the CRT group had advanced T and N stages. The overall response rate to induction TPF was 50.0%; grade 3-4 toxicities included neutropenia, febrile neutropenia, anorexia, and hyponatremia. Complete response rates after CRT completion were 55.5% in the TPF and 42.9% in the CRT group; median overall survival was not reached in the TPF group and was 14.0 months in the CRT group (p = 0.037). Multivariate analysis revealed that induction TPF and T stage were independent prognostic factors [hazard ratio (HR) = 0.196; 95% confidence interval (CI) 0.043-0.898; p = 0.036, HR = 9.966; 95% CI 2.270-43.75; p = 0.002, respectively).
CONCLUSION: TPF followed by CRT is tolerated and may be an option for the treatment of locally advanced stage N2c, N3, or N2b HNSCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248339     DOI: 10.1007/s10147-014-0749-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  19 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.

Authors:  J L Lefebvre; D Chevalier; B Luboinski; A Kirkpatrick; L Collette; T Sahmoud
Journal:  J Natl Cancer Inst       Date:  1996-07-03       Impact factor: 13.506

3.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

4.  Screening for distant metastases in patients with head and neck cancer.

Authors:  R de Bree; E E Deurloo; G B Snow; C R Leemans
Journal:  Laryngoscope       Date:  2000-03       Impact factor: 3.325

5.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

6.  Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.

Authors:  Fabrice Denis; Pascal Garaud; Etienne Bardet; Marc Alfonsi; Christian Sire; Thierry Germain; Philippe Bergerot; Beatrix Rhein; Jacques Tortochaux; Gilles Calais
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

7.  Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.

Authors:  B Brockstein; D J Haraf; A W Rademaker; M S Kies; K M Stenson; F Rosen; B B Mittal; H Pelzer; B B Fung; M-E Witt; B Wenig; L Portugal; R W Weichselbaum; E E Vokes
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

8.  Clinical nodal stage is an independently significant predictor of distant failure in patients with squamous cell carcinoma of the larynx.

Authors:  Jeannette Marie S Matsuo; Snehal G Patel; Bhuvanesh Singh; Richard J Wong; Jay O Boyle; Dennis H Kraus; Ashok R Shaha; Michael J Zelefsky; David G Pfister; Jatin P Shah
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

9.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

10.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

View more
  3 in total

1.  Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.

Authors:  Masahiro Kawahira; Tomoya Yokota; Satoshi Hamauchi; Sadayuki Kawai; Yukio Yoshida; Yusuke Onozawa; Takahiro Tsushima; Akiko Todaka; Nozomu Machida; Kentaro Yamazaki; Akira Fukutomi; Hirofumi Yasui
Journal:  Int J Clin Oncol       Date:  2018-06-15       Impact factor: 3.402

Review 2.  Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.

Authors:  D Alterio; M Cossu Rocca; W Russell-Edu; S Dicuonzo; G Fanetti; G Marvaso; L Preda; S Zorzi; E Verri; F Nole'; B A Jereczek-Fossa
Journal:  Med Oncol       Date:  2017-04-08       Impact factor: 3.064

3.  Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: Two challenging and informative clinical cases.

Authors:  Alyssa M Civantos; Ryan M Carey; Gary R Lichtenstein; John N Lukens; Roger B Cohen; Christopher H Rassekh
Journal:  Head Neck       Date:  2020-04-22       Impact factor: 3.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.